3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
46
Terminated
11
Withdrawn
2
Not yet recruiting
2
Active not recruiting
2
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
32
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Recurrence
4
Immunoglobulin Light-chain Amyloidosis
4
Neoplasms, Plasma Cell
3
Hematologic Neoplasms
3
Renal Insufficiency
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Leukemia, Myeloid, Acute
2
Breast Neoplasms
2
beta-Thalassemia
1
Waldenstrom Macroglobulinemia
1
Thalassemia
1
Plasmablastic Lymphoma
1
Peripheral Nervous System Diseases
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma
1
Leukemia, Plasma Cell
1
Leukemia, Biphenotypic, Acute
1
Burkitt Lymphoma
1
Anemia, Sickle Cell
1
Amyloidosis
1
Acute-Phase Reaction
1
Interventions
Cyclophosphamide
27
fludarabine
18
Rituximab
17
obinutuzumab
11
venetoclax
9
Bendamustine Hydrochloride
9
Lenalidomide
8
zanubrutinib
6
Prednisone
6
Doxorubicin
6
Blood Specimen Collection
6
pembrolizumab
5
fludarabine phosphate
5
Biopsy
5
ibrutinib
4
glofitamab
4
Vincristine
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Exercise
4
loncastuximab tesirine
3
gamma-Globulins
3
axicabtagene ciloleucel
3
acalabrutinib
3
Temozolomide
3
Surveys and Questionnaires
3
Palliative Care
3
Mycophenolic Acid
3
Methotrexate
3
Mesna
3
Magnetic Resonance Spectroscopy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Lymphoma
×
Bortezomib
×
Clear all
NCT04915248
2026-06-02
FIL_DALYA
Fondazione Italiana Linfomi - ETS
Phase 2
Recruiting
28 enrolled